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Abstract: Recently, treatment with MEK inhibitors has been shown to
be an effective treatment option for metastatic melanoma. Treatment
efficacy is dependent on inhibition of MAPK-related melanoma pro-
liferation. However, targeting of MEK can be accompanied by a time-
dependent and reversible serous retinopathy of unknown origin.
We analyzed the molecular mechanism by which the MEK inhibitor
binimetinib may lead to retinopathy, using neuroretina and cell models
of retinal pigment epithelium (RPE).
Binimetinib inhibited the MAPK pathway while discontinuation of
treatment resulted in reactivation. However, cell proliferation was not
inhibited correspondingly during binimetinib treatment of ARPE19
cells. Remarkably, post-mitotic neuroretinal tissue displayed a strong
MAPK activation that was lost after binimetinib treatment.
We propose that binimetinib-associated retinopathy is correlated with
inhibition of the MAPK pathway in multiple retinal components. Retinal
cellsareabletoregain theactivationafterbinimetinibtreatment,mimicking
the reversibility of the retinopathy. Asmost retinal cells are nonregenerat-
ing, other mechanisms than stimulation of proliferation must be involved.
(Medicine 95(18):e3457)
Abbreviations: CO2 = carbon dioxide, DMEM = Dulbecco’s
modified eagle’s medium, ERK = extracellular signal-regulated
kinase, MAPK = mitogen-activated protein kinase, MEK =
mitogen-activated protein kinase kinase, PVDF = polyvinylidene
fluoride, RPE = retinal pigment epithelium, SEM = standard error
of the mean, SRF = subretinal fluid, TGX = tris-glycine extended.
INTRODUCTION
I nhibitors of MEK, such as binimetinib, have proven to be aneffective treatment for patients with metastatic melanoma.1
However, serous retinopathy is a common complication of bini-
metinib.1–4Binimetinib-associatedserous retinopathydevelops in
up to 77% ofmetastatic cutaneous melanoma patients and in 60%
ofmetastaticuvealmelanomapatients.2Althoughthecentralretina
(macula) was affected in most patients, only 22%of all patients in
our previous clinical study developed visual complaints. Dose
reduction or discontinuation of the treatment with binimetinib led
to the disappearance of complaints and subretinal fluid (SRF) in
mostpatients.Thesymptomsrecurredinmostcasesafter restarting
the treatment (Figure 1A). However, despite continuation of
administration of binimetinib in the other patients, resolution of
both complaints and lesions occurred.2 Electro-oculography,
which is an indirect measurement of RPE cell function, was
found to be abnormal in virtually all cases over a prolonged
period. This indicates that binimetinib may induce persistent
panretinal RPE cell dysfunction, despite resolution of SRF.2,3
Other MEK inhibitors such as trametinib, cobimetinib, and
RO5126766 can also cause a similar retinopathy. This suggests
that the development of retinopathy is not restricted to bini-
metinib, but related to the class of MEK inhibitors.4–8 This
retinopathy is thereby most likely to be an on-target effect of
MEK inhibition and may reflect the treatment efficacy. How-
ever, no relationship between occurrence of serous retinopathy
and both overall survival and progression-free survival of
cutaneous melanoma patients has been found.2 Despite the fact
that activation of the MAPK pathway has only been observed in
pathologic RPE, binimetinib-associated serous retinopathy
occurs in eyes without a history of other ophthalmological
diseases.1 A possible role for the MAPK pathway in the
neuroretina has not been described yet. A better understanding
of the underlying molecular mechanisms of the treatment
enables the improvement of risk estimation of therapeutic effect
in nonpathologic tissues. Therefore, we set out to analyze
MAPK activation in RPE and neuroretina as a possible mech-
anism by which binimetinib causes serous retinopathy.
MATERIALS AND METHODS
Cell Culture
ARPE19 cells were cultured in order to serve as a positive
control, exhibiting MAPK activity.9 Cells were cultured in
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DMEM/F-12 plus GlutaMax medium (Life Technologies,
Carlsbad, CA) supplemented with fetal calf serum (Greiner
Bio-One, Kremsmu¨nster, Austria), penicillin, streptomycin, and
glutamine (all Life Technologies) at 378C with 5% CO2 at
humidified conditions.
To obtain primary neuroretinal tissue, human tumor eyes
were used to perform a separation of the neuroretinal layer and the
choroid–RPE complex. A healthy part of an enucleated tumor eye
was transferred to a CO2-independent medium (Life Technol-
ogies) to harvest the neuroretinal layer. After harvesting, the
neuroretina was divided into 4 pieces and transferred to a
0.4mm Corning Transwell polycarbonate membrane insert
(Sigma Aldrich, St. Louis, MI), already prepared with a drop of
CO2-independent medium. Under each insert 2 mL neurobasal-A
medium (Life Technologies) with penicillin, streptomycin, glu-
tamine, and B27 supplement (Life Technologies) was added.
Beforestarting theexperiment, the tissue culturesweremaintained
at 378C in 5% CO2 at humidified conditions for at least 24 hours to
allow the cells to recover from the dissection.10 The collection of
material for research had been agreed upon by the Medical Ethics
Committee of the Leiden University Medical Center (Leiden, the
Netherlands) and the research protocol adhered to Dutch law and
the current version of the tenets of the Declaration of Helsinki.
Experiments
An in-cell-western assay was performed to analyze the
effect of binimetinib (MW 441.23 g/mole) on cell proliferation
of dividing ARPE19 cells. Besides the DMEM/F-12 plus Glu-
taMax medium with supplements as a control, the binimetinib
dosages 1, 5, 25, 125, and 625 nM were tested. Following 24, 72,
and 144 hours of treatment, the cells were fixed with 4%
formaldehyde and DRAQ5 (Biostatus, Shepshed, UK) was used
to stain the fixed cells. Intensity of DRAQ5 fluorescence was
quantified with the Licor Odyssey infrared imaging system (LI-
COR, Lincoln, NE). In an other experiment, ARPE19 cells were
treated with binimetinib for 24 hours with the concentrations
above. After treatment, binimetinib was replaced by the normal
culture medium in order to allow the cells to recover for 24 or
168 hours.
After culturing the primary neuroretinal tissue, the medium
was fortified with binimetinib, which was added to the wells
under the inserts. The neuroretinal tissue was treated with 5, 25,
and 125 nM binimetinib for 24 hours.
Following binimetinib treatment, protein of ARPE19 cells
and of the pieces of primary neuroretina was isolated by using
mammalian protein extraction reagent buffer supplemented
with phosphatase and protease inhibitors (Life Technologies).
Ten micrograms of protein was loaded on a mini-protean TGX
gel (4–15%, Bio-Rad, Hercules, CA) with 10 wells, followed by
transfer to a PVDF (low-fluorescence) membrane using the
trans-blot turbo system (Bio-Rad). The primary antibodies used
included mouse-anti-phospho-p44/42 ERK antibody (Sigma
Aldrich), rabbit-anti-p44/42 ERK antibody (Cell Signalling
Technologies, Danvers, MA), mouse-anti-vinculin antibody
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FIGURE 1. Illustration of the reversibility of binimetinib-associated serous retinopathy. (A) Ophthalmic imaging of the retina during
binimetinib treatment of a 56-year-old female with metastatic cutaneous melanoma. At initial screening, the patient had a normal overall
arrangement of the retinal layers (1). Eleven days after start of treatment an accumulation of subretinal fluid (SRF) had developed (2).
Besides seeing dark flecks, the patient did not have ocular complaints. Thirty days after treatment started, SRF had disappeared despite
continuation of medication (3). After discontinuation and restart of medication recurrence of SRF occurred (4), and (permanent)
disappearance of SRF could be detected upon discontinuation of treatment due to a bad physical condition of the patient (5, 6). (B) Mild
growth inhibition of ARPE19 cells upon increasing concentrations of binimetinib. Bars representmeanwith SEM, control (0 nM) was set to
100%, and the intensities were corrected for background.

P<0.05 compared to control (0 nM), and #P<0.05 compared to treatment
with 125nM. (C) Regain in ERK phosphorylation after 24 and 168hours of recovery after treatment of ARPE19 cells with binimetinib. Both
during treatment and recovery, vinculin expression was stable. ERK¼ extracellular signal-regulated kinase, SEM¼ standard error of the
mean, SRF¼ subretinal fluid.
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(Sigma Aldrich), and rabbit-anti-calbindin-D28K antibody
(Cell Signalling Technologies). The secondary antibodies used
were goat–anti-mouse 800 nm antibody and goat–anti-rabbit
680 nm antibody (LI-COR). The fluorescence intensity was
measured using the Licor Odyssey infrared imaging system.
Statistical Analysis
Statistical analysis of the results was performed in SPSS
Statistics (IBM, version 23.0) using a nonparametric Mann–
Whitney test to determine significance between different bini-
metinib concentrations. P-values <0.05 were considered to be
statistically significant.
RESULTS
Although no significant growth inhibition was observed
(Figure 1B), ERK activation in ARPE19 cells decreased with
increasing binimetinib concentrations (Figure 1C). Expression
of total ERKwas not affected by binimetinib treatment (data not
shown), but a complete loss of ERK activation was observed.
The analysis of the reversible nature of the binimetinib-
associated serous retinopathy in the ARPE19 cell line showed a
decrease in ERK activity after 24 hours of binimetinib treatment
with increasing concentrations (Figure 1C). Both 24 and
168 hours after discontinuation of binimetinib treatment, an
increase in ERK activity was found, compared to immediately
after the cessation of binimetinib treatment. The increase in
ERK activity was similar for all concentrations of binimetinib
(Figure 1C). This experiment showed the ability of ARPE19 to
recover from binimetinib treatment within 24 hours.
Primary neuroretinal tissue, unexpectedly, displayed acti-
vated ERK (Figure 2A). A reduction in ERK activity was
observed in all 7 tested neuroretinas following binimetinib
treatment with increasing concentrations (Figure 2A and B).
Binimetinib treatment at 25 and 125 nM significantly decreased
ERK activity (P¼ 0.004 and P< 0.001, respectively). Calbin-
din antibody was used to validate the presence of neuroretinal
tissue in all 7 tested samples by staining the ganglion cell layer,
the inner nuclear layer, and the outer nuclear layer. Calbindin
and total ERK expression were not affected by binimetinib
treatment (Figure 2A and B).
DISCUSSION
Based on the results of this study, we propose that the
binimetinib-associated serous retinopathy represents a class
effect of MEK inhibitors and that it therefore is most likely
to be an on-target side effect. This leads to the challenging
hypothesis that MAPK activation is playing a role in the retina,
an essentially nonregenerating tissue.
We analyzed MAPK activation in a RPE cell line model
and in primary neuroretina to investigate involvement ofMAPK
inhibition in serous retinopathy. We revealed ERK activation in
both ARPE19 and primary neuroretina. ERK activation in
ARPE19 cells has been observed before,11 and gene expression
analysis of primary RPE cells has suggested a broad functional
role for ERK.12 ERK activation in neuroretina has not pre-
viously been described. Binimetinib treatment inhibits ERK in
both the neuroretina and the RPE cell model. This potentially
involves MAPK inhibition in the development of MEK-associ-
ated serous retinopathy. During recovery from the binimetinib
treatment, ERK activation increased in the RPE model, at all
concentrations. The in vitro ability to recover from treatment
mirrors the disappearance of the serous retinopathy after
treatment discontinuation. Upon resuming binimetinib treat-
ment, serous retinopathy and visual symptoms often recurred.
However, in some patients resolution of SRF occurred spon-
taneously despite continued treatment (Figure 1A).2 This time-
dependent and self-limiting nature of the serous retinopathy
suggests redundancy of ERK during prolonged MEK
inhibitor treatment.
Binimetinib-treated patients display irreversible electro-
oculography abnormalities, reflecting an impaired standing
potential of the RPE and RPE dysfunction.2,3 Normally, the
RPE prevents SRF accumulation by maintaining the outer
blood-retinal barrier and by regulating ion channels.13 Tight
junctions between the RPE cell monolayer that enable the RPE
to form the outer blood-retinal barrier are regulated by the
MAPK pathway.14 A factor that is involved in this process is the
fluid transport channel aquaporin 1 that was specifically shown
to be regulated by the MAPK pathway.15 The prolonged RPE
dysfunction together with serous SRF accumulation that is
observed in binimetinib treated patients may be explained by
these mechanisms.
The clinical phenotype may also originate from abnorm-
alities induced in the neuroretina, as we observed a strong
activation of ERK in primary neuroretinal tissue. ERK is a
neuroprotective regulator in the neuroretina and could be
involved in the maintenance of a normal neuroretina-RPE
interaction.16,17 ERK activity may also play a role in mainten-
ance of the inner blood-retinal barrier that lines the retinal
vasculature, by regulating tight junctions similar to the RPE
outer blood-retinal barrier. Only few cases that developed a
retinal vein occlusion during MEK inhibitor treatment have
been described.2,3,5,7,18
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FIGURE 2. ERK activation in nonregenerative primary neuroret-
inal tissue. (A) Binimetinib reduced ERK activity (P-ERK) in primary
neuroretinal tissue. MEK inhibition had no effect on the expression
of calbindin, vinculin, and total ERK. (B) In all 7 neuroretinas, a
reduction in ERK activity was observed after treatment with
binimetinib. The differences in activity after treatment with bini-
metinib concentrations of 25 and 125nM, when comparing to
0nM, were significant (P¼0.004 and P<0.001, respectively).
Between the binimetinib concentrations, no significant difference
was seen in total ERK expression. The integrated intensities of both
ERK and total ERK were corrected for vinculin ([{p}ERK/vinculin]
100). Bars represent mean with SEM.

P<0.05 compared to
control (0 nM), and

P>0.05 compared to control (0 nM).
ERK¼ extracellular signal-regulated kinase, MEK¼mitogen-
activated protein kinase kinase, SEM¼ standard error of themean.
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Treatment consisting of both BRAF and MEK inhibitors
improves efficacy in treating metastatic melanoma as the
addition of a MEK inhibitor neutralizes the paradoxical MAPK
pathway activation that occurs due to BRAF inhibition.6 For
that reason, combination treatment reduces the risk of tumor-
igenesis in other tissues, such as the development of squamous
cell carcinoma.19 However, the occurrence of a treatment-
associated serous retinopathy increased with this combination,
supporting the notion that this adverse event is most likely to be
an on-target treatment effect of MAPK targeted drugs.20
In conclusion, MEK inhibitors such as binimetinib can
cause a rapid-onset serous retinopathy in patients with meta-
static melanoma, which is at least partially reversible. In
monocular uveal melanoma patients, the functional visual
impact may be clinically the most relevant. It is essential to
unravel the (molecular) origin of this adverse event to be able to
prevent it, for example, by means of a dose reduction in
symptomatic patients.
Our findings show that the retinopathy may be caused by
reversible suppression of ERK activity in neuroretina and RPE,
which could lead to disturbances in the neuroretina–RPE
interaction and to the occurrence of SRF. The strong activity
of ERK in primary neuroretinal tissue indicates that ERK has
other functions besides regulation of cell proliferation, as
neuroretina represents post-mitotic neural tissue. Inhibition of
retinal ERK activity appears to be a key component in the
pathogenesis of MEK-associated serous retinopathy.
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